Stifel analyst Stephen Willey initiated coverage of OmniAb with a Buy rating and $12 price target. OmniAb "represents the construction of a high-throughput antibody discovery platform" via over 10 years of focused investment and strategic acquisitions, Willey tells investors in a research note. The analyst believes the spin-off of OmniAb from Ligand "creates an opportunity to unlock additional value and better-position the company for future growth."
Published first on TheFly
